<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 295 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page294.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=295">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 295 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 295</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=295"><img src="../thumb/295.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>258 / 2020-04                                                            Anti-Microbials - 18.11
   (S4) TABS 34/20.2.6/0161     (S4) SUSP, [P/S] F/20.2.6/50. 200 mg/5 ml.  may cause hypoglycaem. & freq.bld gluc.monit.necess., poss. risk
   876089-007: 24, R361,83      726338-001: 100 ml, R167,12   of neurologic.sequel.e.g. convuls., post-treatm. haemolyt. anaem.,
   Dosage: Take with food/fluids high in fat. Rep. dos.if vomit. within   Dosage: Take tabs.with/aft.food, & susp.at least 1 hr. bef.food.  treatm.of sev.life-threaten. malar. in pregn.only indicat.when other
   1 hr.of admin.               UG trichom: Adults: 2 g as sngl.dos., or 200 mg 3xdly or 400 mg   safer anti-malar. meds not avail./inappropr., do not reconstit. us-
   Intens.3 day course recomm. Init. 1-4 tabs.as sngl. dos. depend. on bm   2xdly.x7 days or 800 mg in morn. & 1,2 g in even.x2 days. Childr. 7-10   ing water for inj.
   rep.aft.8 hrs.thereaft. 2x dly.on follow.2 days. Tot.course comprises   yrs: 100 mg 3xdly x7 days.  See also MDR page 304.
   6, 12, 18 or 24 tabs. depend.on bm. 5-&lt;15 kg: Init. 1 tab. rep. aft. 8   3-7 yrs: 100 mg 2xdly x7 days.
   hrs. thereaft.2x dly.(morn.& even.) on follow.2 days. Tot: 6 tabs. 15-  1-3 yrs: 50 mg 3xdly x7 days.  MALANIL, Litha [P/S]
   &lt;25 kg: Init. 2 tabs. as sngl.dos.rep.aft.8 hrs.thereaft.2x dly. (morn.&   Non-specif.vaginit: Adults: 2 g as sngl.dos.or 400 mg 2xdly x7 days.  Atovaquone 250 mg, proguanil HCl 100 mg.
   even.) on follow.2 days. Tot:12 tabs. 25-&lt;35 kg: Init.3 tabs.as sngl.  Amoebias: Depend.on type & subj. Adults:   Indications: Prophylax.of drug sensitive & drug resist.P.Falciparum
   dos.rep.aft.8 hrs. thereaft. 2x dly.on follow.2 days.(morn.& even.) Tot:   400-800 mg 3xdly x5-10 days. Childr. 7-10 yrs: 200-400 mg 3xdly   malaria in conjunct.with official guidelines & loc.info.on preval.of
   18 tabs. 35-&lt;65 kg: Init. 4 tabs.as sngl.dos. rep. aft. 8 hrs. thereaft.   x5-10 days. 3-7 yrs:   antimalar. drug resist.
   2x dly.(morn.& even.)on follow.2 days. Tot: 24 tabs.  100-200 mg 4xdly x5-10 days. 1-3 yrs:   (S2) TABS, 37/20.2.6/0075
                    nd
   New & recrudescent infects: Admin.2  course.  100-200 mg 3xdly x5-10 days.  700780-001: 12, R310,50
   Contra-indications: No adeq.exper.in pts. weigh &gt;65 kg./in com-  Giardias: Adults: 2 g dly x3 days. Childr. 7-10 yrs: 1 g dly.x3 days.   Dosage: Must be taken with food at the same time. Rep.dos.if vomit.
                     st
   plic.malaria., sev.malaria accord.to WHO, 1  trimest.pregn.where   3-7 yrs: 600-800 mg dly.x3 days.  occurs within 1 hr.of dos. Commenc.1-2 days bef.enter.area and cont.
   other suit./effect.anti-malar.avail., other concom. drugs/ clinic.con-  1-3 yrs: 500 mg dly.x3 days.  dly.x7 days aft.leav.area.
   dit./congenit.fam.hist known to prolong QTc interv., known.electrol.  Ulcerat.gingivit: Adults: 200 mg 3xdly.x3 days. Childr. 7-10 yrs:   Adults &gt;40 kg: 1 tab.dly.
   bal.disturb., drug metabol.by cytochrome.enzyme CYP2D6, lactat.&   100 mg 3xdly for 3 days. 3-7 yrs: 100 mg 2xdly. for 3 days.  (S2) PAED.TABS, A40/20.2.6/0165
   breastfeed, prophylax., safety & effic.in sev.hepat./ ren.insuffic.& el-  1-3 yrs: 50 mg 3xdly. x3days.  Atovaquone 62,5 mg, proguanil HCl 25 mg.
   derly not est., concom. antimalarials other than mefloquine or quinine.  Ac.pericoronit: Adults 200 mg 3xdly. x3-7 days.  711525-001: 12, R203,12
   Side-effects: Tetratogen.potent.dur.early gestat., palpits., GI dis-  Anaerob.infects. Treatm: Adults: Init.800 mg follow.by 400 mg   Dosage: Must be taken with food at the same time. Rep.dos.if vomit.
   turbs., hypersens., arthralg., myalg., CNS effs., anorex., sleep dis-  8 hrly.x7 days or long.depend.on clinic.& bacteriolog.assesm.of pts.  occurs within 1 hr.of dos. Commenc.1-2 days bef.enter.area and cont.
   ords., mood swings, gait abnorm., cough., prurit., rash, asthen.,   condit. Childr: 7,5 mg/ kg bm 8 hrly.or long.depend.on clinic.& bac-  dly.x7 days aft.leav.area.
   fatig., unspecif.personal. disords.in childr. und.5 yrs., asymptomat.  teriolog.assesm.of pts.condit.  Childr: 11-20 kg: 1 tab.dly. 21-30 kg: 2 tabs.as sngl.dly.dos. 31-40 kg:
   QTc-prolongat., incr.LFT, invol.musc.contracts.  Prevent: Adults: 400 mg 8 hrly x24 hrs.pre-op. Childr: 7,5 mg/  3 tabs.as sngl.dly.dos.
   Warnings and special precautions: Consid. risk vs benef.dur. 2   nd  kg bm 8 hrly.  Contraindications: Sev.ren.impairm., concom. rifampicin/ rifabutin,
   & 3  trimest.pregn., women of child-bear. potent.to pract.contracept.  Post-op: IV/rect.admin.till oral therapy poss.  safety in pregn.& lactat.not est.
    rd
   dur. travel with stand-by emerg.treatm.while on COARTEM.until start   H.pylori-assoc.gastrit.& duod.ulc: Treatm: Colloidal bismuth sub-  Side effects: Bld dyscras., skin rash, uticar., angioed., anaphylax.,
   of next menstruat.aft. treatm., do not resume breastfeed.bef.day 28   citr 108 mg, tetracycline HCl 500 mg, Flagyl 250 mg (ie.6,25 ml Flagyl   vasculit., photosensit., Stev.-Johns.Syndr., hyponatraem., anorex.,
   aft.ther., not eval.for cerebr.malaria/sev. complicat.malarial effs.incl.  susp.) 4xdly.x14 days or colloid.bismuth subcitr.108 mg, tetracycl.HCl   elev. amylas. lev., headache, insomn., dizzin., convuls., psych. dis-
   pulm.oed./ren.fail., recrudesc.risk great.in pts.remain.averse to food.,   250 mg, Flagyl 200 mg 5xdly.x14 days.  ords., GI disturbs., oral ulcerat., stomatit., hepatit., elev.liv.enzyme
   start altern.treatm.immed.if condit.deteriorat.& monit.ECG/correct.   (S4) SUPP, [P/S] K/20.2/15,16  lev., cholestas., hair loss, fev., cough.
   any electrol.disturbs., admin. not earlier than 1 mnth.aft.last halofan-  Indications: Anaerob.bact.infects., post-op prophylax. of anaerob.  Warnings and special precautions: Breast feed.not recomm.,
   trine dos., concom. substrates/inhibit./induc.of CYP3A4, monit.food   infects.in gynae.,colon surg. & appendicect.  safety & effectiven.not est.in adults &lt;40 kg & paed. tabs.in chil-
   intake (mefloquine) or ECG (quinine) when given sequent.to these   726303-003: 500 mg, 10, R224,94  dr.&lt;11 kg, treat with diff. schizonticide if recrudesc.infects.due to
   agents, consid. lumefantrine’s long eliminat.half-life when admin.  726311-006: 1 g, 10, R357,19  P.falciparum occur/chemoprophylax.fails, cont. with person.protect.
   quinine to pts.prev.treat.with COARTEM, in P.vivax.not act.against   Dosage: Where oral medicat.not poss./contra-indicat.  meas.(ie.repell.) if diarrh.or vomit. occur, no studies conduct.in sev.
   hypnozoites theref. sequent. treatm.with appropr.antimalar.necess.   Treatm: Adults: 1 g pr. 3xdly x7 days or long.until feed.is poss.   hepat. impairm., hist.of epilep., stop treatm.at first sign of ser.skin
   with P.vivax co-infect., unable to confirm if QTc prolongat.seen in   Childr: 7,5 mg/kg bm. (1-5 yrs: 250 mg, 5-10 yrs: 500 mg) pr.8 hrly.  rash/in case of blister./mucosal involvem.
   childr.& infts.weigh.betw.5-25 kg & pts.suffer.from dehydrat./elec-  x3 days then 12 hrly.  Drug interactions: Tetracycl./metoclopramide/ rifampicin & rib-
   trol. imbal.due to dis./COARTEM.  Prevent: Adults: 1 g pr. 2-4 hrs.pre-op. & 8 hrly. till oral therapy poss.  abutin decr.atovaquone plasma conc., trough lev.of indinavir decr.,
   Drug interactions: QTc prolongat.risk.assoc. with IV quinine enhanc.  (200 mg 3xdly.) Childr: As describ. und.treatm.pr.2-4 hrs.pre-op.& 8   proguan.may potent.anticoag.eff.of warfarin & other coumarin
   by prior COARTEM admin., signif.reduct.in Cmax & AUC of lumefan-  hrly.till oral therapy poss.(7,5 mg/kg 8hrly.)  based anticoags.
   trine with sequent.oral admin.of mefloquine prior to COARTEM, lu-  (S4) IV INFUS, [P/S] J/20.2/151.  MALATEQ, Forrester Pharma [P/S]
   mefantrine inhib. CYP2D6 in vitro.  779539-001: 500 mg/100 ml, R12,39  Atovaquone 250 mg, proguanil HCl 100 mg.
   DARAPRIM, GSK [P/S]          Dosage: Treatm: Adults & childr.over 12 yrs: 500 mg infus.at 5 ml/  Indications: Prophylax.of drug-sens.& drug-resist.P.Falciparum
   Pyrimethamine.               min.rep.8 hrly. Childr.und.12 yrs: 7,5 mg/kg bm IV.  malaria in conjunct.with official guidelin.& loc.info.on preval.of an-
   Indications: In combinat.with sulphapyrimidine-type sulphona-  Prevent: Adults & childr.over 12 yrs: 100 ml immed. bef., dur/aft.  timalar. meds. resist.
   mide in treatm.of Toxoplasmosis caus. by toxoplasma gondii. Not   op follow.by same dos. 8 hrly till oral medicat.poss. Childr.und.12   (S2) TABS, A47/20.2.6/1015
   for malaria prophylax.       yrs: As for adults bas.on 7,5 mg/kg bm.  720918-001: 12, R294,18
   (S4) TABS. A682.             Contraindications: Safety in pregn.& lactat.not est., other imida-  Dosage: Admin.with food/milk at the same time dly. Rep.dos.if vomit.
   717517-012: 25 mg, 60, R340,52  zoles.. co-admin.with busulfan.  occurs within 1 hr.of dos. Adults: 1 tab.dly.
   Dosage: Admin.folate supplem.as Ca folinate where poss.to reduc.  Side effects: GI disturbs.incl.taste disords., dry mouth, furred tong.,   Commenc.1-2 days bef.enter.malaria-endem.area and cont.dly.x7
   bone marrow depress.risk.    oral mucosit./stomatit., pseudomembr.colit., headache, periph.neu-  days aft.leav.area.
   Adult AIDS pts: Load.dos: 100-200 mg/day in combinat. with   ropathy / epilept.seiz.esp.with prolong.use, psych. disturbs., weakn.,   Contraindications: Sev.ren.impairm., safety in pregn.& lactat.not
   500 mg-1,5 g sulphadiazine 6 hrly. Treatm: 50-100 mg/day in com-  dizzin., atax., drowsin., insomn., mood/ment.state chang., bld.dys-  est., safety & effic.in pts.&lt;40 kg not est., concom.rifampicin/rifabutin
   binat.with 500 mg-1,5 g sulphadiazine 6 hrly. Maint: 25-50 mg/day   cras., skin reacts., fev., angioed., flush., anaphylax., serum sickn.-like   not recomm., no studies in sev.hepat.impairm.
   in combinat.with 250 mg-1 g sulphadiazine 6 hrly.  sympt., myalg./arthralg., vis.disturbs., nas. congest., pancreat., urethr.  Side effects: Bld.dyscras., angioed., hyponatraem., GI disturbs.,
   Other pts: Load.dos: 50-200 mg/day in combinat. with 250 mg-1 g   discomf., dark.urine, cholest. hepatit., urticar., anorex., encephalopa-  oral ulcer., stomatit., elev. liv.enzym., headache, insomn., fev., skin
   sulphapyrimidine-type sulphonamide. 6 hrly x1-2 days. Treatm: 25-  thy, subac. cerebell.syndr.  reacts., cough, alopec.
   50 mg/ day in combinat.with 125-500 mg sulphapyrimidine-type   Special precautions: Bld.dyscras., act./chron. central & periph.nerv.  Warnings and special precautions: Maint.gen. malar. prophy-
   sulphonamide 6 hrly. x2-4 wks. if immunocompetent/ 4-6 wks.if   syst.dis., monit.treatm.if more than 10 days, discont.if signs of periph.   lact. meas.when visit.areas known /susp. to be malaria infect., con-
   immunocomprom. Paed: In combinat.with usual paed. sulphapy-  neuropath./CNS toxic.develop, sev.liv.dis., psychot. reacts.report.with   com.indinavir, treat with diff. bld. schizonticide if recrudesc.infects.
   rimidine type sulphonamide dos. 1 mg/kg bm.dly x1-3 days, then   concurr.disulfiram., may mask immunologic.respons.of untreat.early   occur due to P.falciparum chemoprophylax.fail., poss. reduc.absorpt.
   0,5 mg/kg bm dly. x4-6 wks.  syphil., condom latex liable to rupt.with simultan.supp. use, avoid   with diarrh.& vomit., contin. with person.protect.meas.(ie.repell.) if
   Confirm.congenit.toxoplasmos: Contin.for min. x6 mnths.if no   alcoh.dur.& for 1 day aft.ther., Also 400 tabs: contains tartrazine.  diarrh./ vomit. occur.
   sign of infect.or x1 yr.if signs of signific. infect.pres.  Drug interactions: Eff.of warfar.enhanc., phenytoin / Li/fluorouracil   Drug interactions: Tetracycl./metoclopramide/ rifampicin & rib-
   Side effects: Bld.dyscras., gastrit.& atroph. glossit.with larger dos.,   clear.imp., phenytoin poss.acceler.metronidazole metabol., pheno-  abutin poss.decr.atovaquone plasma conc., decr.indinavir trough lev.
   GI disturbs., headache, dizzin., dry mouth/throat, fev., malaise, der-  barb. decr.plasma conc., cimetidine incr.plasma conc., cyclospor.ser.
   matit., abnorm.skin pigmentat., depress., sev.& sometim. fatal reacts.  lev.poss.incr., poss.disulfiram-like react.with alcoh.  MEFLIAM, Cipla Medpro [P/S]
                                                              Mefloquine HCL equiv.to mefloquine.
   report., hyperphenylalaninaem.in neonates, erythema multiforme,   GARSUN, Equity &  Indications: Malaria prophylax.where resist.to chloroquine, progua-
   Stev.-Johns. syndr., tox.epiderm.necrolys., hepat.toxic., pneum. in   Artesunate   nil & pyrimethamine-sulfonamide combinat.
   combinat.with other products.  Indications: Sev. malar. caus. by Plasmodium falciparum in   (S4) TABS. 31/20.2.6/0502.
   Special precautions: Hepat./ren.disords., folate defic., wkly.FBC   adults & childr.  835552-004: 250 mg, 6, R127,33
   dur.therapy & for 2 wks.aft. treatm. stopp., adeq.fluid intake with sul-  (S4) SOL. FOR INJ, 48/20.2.6/0866.  Dosage: Take with food. 1st dos. 1 wk.bef.arriv. in endem.area and
   phonamid., elderly poss.more suscept.to folate depress., discont.if
   rash appears, seiz.disords. hist., weigh benef.-risk ratio in pregn., ex-  723395-001: 60 mg, 1 vial, R489,32  subseq.wkly.dos.on same day of each wk. Contin.for 4 wks.aft.leav.
                                Dosage: 2.4 mg/kg by IV inject.at 0, 12 & 24 hrs, then once dly.until
                                                              area but not exceed. 3 mnths.in durat.
   cret.in breast milk & may interfer.with folic acid metabol.in nurs.infts.
   Drug interactions: Bone marrow depress. enhanc. with other folate   oral treatm.can be substitut. Admin for minim.24 hrs (3 dos.) regard-  Up to 19 kg: ¼ tab. 20-30 kg: ½ tab. 31-45 kg: ¾ tab. &gt;45 kg: 1 tab.
                                less of pt’s ability to toler.oral medicat.earlier. After at least 24 hrs.
                                                              Contraindications: Pregn.& lactat., quinine hypersens., psych.
   antagon.e.g.co- trimoxazole/phenytoin, lorazepam may induc. hepa-
   totox., protein bind.other compds.poss. prevent., may exacerb.myelo-  & when pt.able to toler.oral medicat.pt should be put on a complete   disturb./convuls.hist., childr. with bm &lt;5 kg./ &lt;3 mnths., imp.liv./ren.
                                treatm.course with a combinat.of appropr.antimalar.meds.
                                                              funct., quinine & quinidine used for sev.malaria treatm. contra-indic.
   suppress.eff.cytostat agents esp.antifol.methotrex.
                                Contraindications: Not evaluat.in treatm.of sev. malar. due to   when Mefliam prophylax.has been used.
   FLAGYL, Sanofi-Aventis [P/S]  Plasmodium vivax/ Plasmodium malariae/ Plasmodium ovale.,   Side effects: CNS eff., GI disturbs., vis.disturbs., card.eff., hair loss,
   Metronidazole.               pregn. & lactat., IV infus.   rash, prurit., urticar., convuls., psycholog.chang., bld.dyscras., erythe-
   Indications: Oral treatm.of urogenit. trichomonias., non specif.  Side effects: Allerg.reacts, bld.dyscras., dizzin., light-headedn.,   ma multiforme, Stevens-Johnsons syndr., paraesthes.
   vaginit., all forms of amoebias., giardiasis, ac.ulcerat.gingivit., ac.   headache, insomn., tinnit.(with/-out decr.audit.funct.), convuls., pe-  Special precautions: Discont.breast feed.as excret.in breast milk,
   pericoronit., anaerob.infects., post-op prophylax. anaerob.infects.in   riph.neuropathy, cough, nasal sympts., GI disords., incl.pancreatit.,   contracept.dur.prophylax.& for 3 mnths.follow.last dos., period.liv.
   gynae.,colon surg.& appendicect., H.pylori-assoc.gastrit.& duod.ulc.  trans. rise in hepat.transaminas., hepatit., rash, alopec., arthralg.,   funct.tests if tak.for long.than 3 mnths., card.conduct.dis., driv./op-
   in combinat.with bismuth subsalicylate or colloid. bismuth subcitrate   musc.disords., fatig., malaise, fev., pain at inj.site.  erat.machin., scuba div.& pilot.aircraft due to report.dizzin., discont.
   & appropr.antibiot.therapy.  Warnings and special precautions: Always follow ac.treatm.  if unexpl.anx., depress., restlessn./confus.noticed, potent.fatal QTC
   (S4) TABS, [P/S] A370, D/20.2.6/228.  with a complete treatm.course of an appropr.oral combinat.antima-  interv. prolongat.if concom.halofantrine used, pref. prophylax.should
   726346-004: 200 mg, 21, R59,77  lar.regimen., hepat./ ren.impairm., use reconstit.sol.within 1 hr. of   not to exceed 3 mnths in durat., resistance document., seek medic.
   726354-007: 400 mg, 10, R60,69  prep., consid.country specif.guidelines on preval. of resist.to anti-  advice if flu-like sympts.develop, imp.hepat./ ren.funct., check relev.
   726354-015: 400 mg, 100, R606,82  malar.in choos.the appropr. combinat. antimalar.regim., sev.malar.  paramet.in pts.tak.anticoags.& oral antidiab. bef.admin.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page294.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page290.html">290</a>&nbsp;&nbsp;&nbsp;<a href="page291.html">291</a>&nbsp;&nbsp;&nbsp;<a href="page292.html">292</a>&nbsp;&nbsp;&nbsp;<a href="page293.html">293</a>&nbsp;&nbsp;&nbsp;<a href="page294.html">294</a>&nbsp;&nbsp;&nbsp;<a href="page295.html">295</a>&nbsp;&nbsp;&nbsp;<a href="page296.html">296</a>&nbsp;&nbsp;&nbsp;<a href="page297.html">297</a>&nbsp;&nbsp;&nbsp;<a href="page298.html">298</a>&nbsp;&nbsp;&nbsp;<a href="page299.html">299</a>&nbsp;&nbsp;&nbsp;<a href="page300.html">300</a>
             </td>
             <td width="35%"><a href="page296.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page296.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
